Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 9/2014

01-09-2014 | Thoracic Oncology

Outcomes of Preoperative Chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil Followed by Esophagectomy in Patients with Resectable Node-Positive Esophageal Cancer

Authors: Masayuki Watanabe, MD, PhD, FACS, Yoshifumi Baba, MD, PhD, Naoya Yoshida, MD, PhD, FACS, Takatsugu Ishimoto, MD, PhD, Yohei Nagai, MD, PhD, Masaaki Iwatsuki, MD, PhD, Shiro Iwagami, MD, PhD, Hideo Baba, MD, PhD, FACS

Published in: Annals of Surgical Oncology | Issue 9/2014

Login to get access

Abstract

Background

There is a consensus that neoadjuvant therapy is an essential component of treatment for resectable advanced esophageal cancer. The aim of this study was to evaluate the efficacy of preoperative docetaxel/cisplatin/5-fluorouracil (DCF) followed by esophagectomy for patients with node-positive esophageal cancer using a prospective database.

Methods

Fifty-five consecutive patients with resectable node-positive esophageal cancer were treated with preoperative DCF between August 2008 and December 2010. Of these patients, 54 completed 2 courses of DCF, and 50 underwent esophagectomy after the planned chemotherapy. Clinical and pathologic responses to DCF were investigated, as was patient prognosis. Cox proportional hazard regression was used to determine factors that independently affected recurrence.

Results

Complete response, partial response, stable disease, and progressive disease were observed in 5, 24, 24, and 2 patients, respectively. Overall, the clinical response rate was 53 %. Pathologic complete response was achieved in 6 cases (12 %), and the overall pathologic response rate was 36 %. Downstaging was observed in 23 cases (46 %). Two-year overall and disease-free survival rates were 78 and 56 %, respectively. Multivariate analysis revealed that residual tumor [R1/2; hazard ratio (HR) 5.21, 95 % confidence interval (CI) 1.64–17.2], pathologic poor response (grade 1a; HR 3.08, 95 % CI 1.08–11.1), and ypN (M1Lym; HR 13.3, 95 % CI 2.06–116) were independent predictors of recurrence.

Conclusions

DCF has strong antitumor activity for esophageal cancer and may confer survival benefits when used as preoperative chemotherapy.
Appendix
Available only for authorised users
Literature
1.
Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomized controlled trial. Lancet. 2002;359:1727–33.CrossRef
2.
Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomized controlled phase III trial. Lancet Oncol. 2005;6:659–68.PubMedCrossRef
3.
Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2007;25:2310–7.
4.
Bedenne L, Michael P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus. J Clin Oncol. 2007;25:1160–8.PubMedCrossRef
5.
Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG Trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007;25:3719–25.PubMedCrossRef
6.
van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junction cancer. N Engl J Med. 2012;366:2074–84.PubMedCrossRef
7.
Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8:226–34.PubMedCrossRef
8.
Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;11:681–92.CrossRef
9.
Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study—JCOG9204. J Clin Oncol. 2003;21:4592–6.PubMedCrossRef
10.
Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.PubMedCrossRef
11.
Igaki H, Kato H, Ando N, Shimada M, Shimizu H Nakamura T, Ozawa S, Yabusaki H, Aoyama N, Kurita A, Fukuda H. A randomized trial of postoperative chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus. Paper presented at; 2008 ASCO annual meeting.
12.
Hoffman PC, Haraf DJ, Furguson MK, Drinkard LC, Vokes EE. Induction chemotherapy, surgery, and concomitant chemoradiotherapy for carcinoma of the esophagus: a long-term analysis. Ann Oncol. 1998;9:647–51.PubMedCrossRef
13.
Watanabe M, Nagai Y, Kinoshita K, et al. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for patients with node-positive esophageal cancer. Digestion. 2011;83:146–52.PubMedCrossRef
14.
Tanaka T, Fujita H, Sueyoshi S, et al. Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractorymetastatic esophageal cancer: a preliminary report of initial experience. Chemotherapy. 2007;53:449–53.PubMedCrossRef
15.
Sekiguchi H, Akiyama S, Fujiwara M, et al. Phase II trial of 5-fluorouracil and low-dose cisplatin in patients with squamous cell carcinoma of the esophagus. Surg Today. 1999;29:97–101.PubMedCrossRef
16.
Sobin LH, Wittekind C. TNM classification of malignant tumors. 6th edn. New York: Wiley; 2002. p 60–5.
17.
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.PubMedCrossRef
18.
Japan Esophageal Society. Japanese classification of esophageal cancer. 10th edn. Tokyo: Kanehara; 2008.
19.
Yoshida N, Watanabe M, Baba Y, et al. Influence of preoperative chemotherapy with docetaxel/cisplatin/5-fluorouracil on the occurrence of postoperative complications after esophagectomy for patients with advanced esophageal cancer. Dis Esophagus. In press.
20.
Tachimori Y, Ozawa S, Fujishiro M, et al. Comprehensive registry of esophageal cancer in Japan, 2006. Esophagus. In press.
21.
22.
Stahl M, Budach W, Meyer HJ, et al. Esophageal cancer: clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;21(5):v46–9.
23.
Takahashi H, Arimura Y, Yamashita K, et al. Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma. J Thorac Oncol. 2010;5:122–8.PubMedCrossRef
24.
Yamasaki M, Miyata H, Tanaka K, et al. Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. Oncology. 2011;80:307–13.PubMedCrossRef
25.
Osaka Y, Shinohara M, Hoshino S, et al. Phase II study of combined chemotherapy with docetaxel, CDDP, and 5-FU for highly advanced esophageal cancer. Anticancer Res. 2011;31:633–8.PubMed
26.
Tamura S, Imano M, Takiuchi H, et al. Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403). Anticancer Res. 2012;32:1403–8.PubMed
27.
Donahue JM, Nichols FC, Li Z, et al. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg. 2009;87:392–8.PubMedCentralPubMedCrossRef
28.
Dexter SPL, Sue-Ling H, McMahon MJ, et al. Circumferential resection margin involvement: an independent predictor of survival following surgery for oesophageal cancer. Gut. 2001;48:667–70.PubMedCentralPubMedCrossRef
29.
Chan DS, Reid TD, Howell I, et al. Systematic review and meta-analysis of the influence of circumferential resection margin involvement on survival in patients with operable oesophageal cancer. Br J Surg. 2013;100:456–64.PubMedCrossRef
30.
Tanabe T, Kanda T, Kosugi S, et al. Extranodal spreading of esophageal squamous cell carcinoma: clinicopathological characteristics and prognostic impact. World J Surg. 2007;31:2192–8.PubMedCrossRef
31.
Sakai M, Suzuki S, Sano A, et al. Significance of lymph node capsular invasion in esophageal squamous cell carcinoma. Ann Surg Oncol. 2012;19:1911–7.PubMedCrossRef
32.
Toh Y, Oki E, Minami K, et al. Follow-up and recurrence after a curative esophagectomy for patients with esophageal cancer: the first indicators for recurrence and their prognostic values. Esophagus. 2010;7:37–43.CrossRef
Metadata
Title
Outcomes of Preoperative Chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil Followed by Esophagectomy in Patients with Resectable Node-Positive Esophageal Cancer
Authors
Masayuki Watanabe, MD, PhD, FACS
Yoshifumi Baba, MD, PhD
Naoya Yoshida, MD, PhD, FACS
Takatsugu Ishimoto, MD, PhD
Yohei Nagai, MD, PhD
Masaaki Iwatsuki, MD, PhD
Shiro Iwagami, MD, PhD
Hideo Baba, MD, PhD, FACS
Publication date
01-09-2014
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 9/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3684-8

Other articles of this Issue 9/2014

Annals of Surgical Oncology 9/2014 Go to the issue

Pancreatic Tumors

The Impact of Postoperative Complications on the Administration of Adjuvant Therapy Following Pancreaticoduodenectomy for Adenocarcinoma

Colorectal Cancer

Insight into Mucinous Colorectal Carcinoma: Clues from Etiology

Hepatobiliary Tumors

Comparison of Survival of Patients with BCLC Stage A Hepatocellular Carcinoma After Hepatic Resection or Transarterial Chemoembolization: A Propensity Score-Based Analysis

Breast Oncology

Impact of Bilateral Versus Unilateral Mastectomy on Short Term Outcomes and Adjuvant Therapy, 2003–2010: A Report from the National Cancer Data Base

Gynecologic Oncology

Laparotomy Conversion Rate of Laparoscopic Radical Hysterectomy for Early-stage Cervical Cancer in a Consecutive Series without Case Selection

Pancreatic Tumors

Basing Treatment Strategy for Non-functional Pancreatic Neuroendocrine Tumors on Tumor Size